Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

Key Points

• JPMorgan initiated coverage of Savara with an “overweight” rating and a $12 price target, implying approximately 158% upside from the stock’s $4.65 price. Citigroup also maintained a “market outperform” rating, while analyst sentiment overall remains “Moderate Buy” with an average target of $10.25.
• Savara’s shares were down 2.7%, and the company reported a quarterly loss of $0.16 per share, missing the consensus estimate of a $0.14 loss. Analysts expect a full-year loss of approximately $0.61 per share.
• The clinical-stage biopharmaceutical company is developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis, a rare respiratory disease. Institutional investors own approximately 87.93% of Savara’s outstanding stock.

Stock analysts at JPMorgan Chase & Co. assumed coverage on shares of Savara (NASDAQ:SVRA - Get Free Report) in a report issued on Wednesday, Benzinga reports. The firm set an "overweight" rating and a $12.00 price target on the stock. JPMorgan Chase & Co.'s price target indicates a potential upside of 158.06% from the company's current price.

Other analysts have also recently issued research reports about the stock. Citigroup reiterated a "market outperform" rating on shares of Savara in a research note on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. Royal Bank Of Canada set a $10.00 price target on shares of Savara in a research report on Wednesday. Finally, Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a research note on Sunday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $10.25.

Savara Stock Down 2.7%

SVRA opened at $4.65 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. Savara has a fifty-two week low of $3.34 and a fifty-two week high of $7.01. The firm's fifty day moving average is $5.35 and its 200 day moving average is $5.42. The stock has a market cap of $955.39 million, a price-to-earnings ratio of -8.02 and a beta of 0.20.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, sell-side analysts forecast that Savara will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Principal Financial Group Inc. purchased a new stake in shares of Savara in the first quarter worth approximately $57,000. Sequoia Financial Advisors LLC purchased a new position in Savara during the 2nd quarter valued at $69,000. E Fund Management Co. Ltd. bought a new position in Savara in the 2nd quarter valued at $77,000. Inceptionr LLC purchased a new stake in Savara in the first quarter worth $84,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Savara during the second quarter worth $87,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.